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Abstract
Background: MicroRNAs may act as oncogenes or tumour suppressor genes, which make these small molecules
potential diagnostic/prognostic factors and targets for anticancer therapies. Several common oncogenic microRNAs
have been found for canine mammary cancer and human breast cancer. On account of this, large-scale profiling of
microRNA expression in canine mammary cancer seems to be important for both dogs and humans.
Methods: Expression profiles of 317 microRNAs in 146 canine mammary tumours of different histological type,
malignancy grade and clinical history (presence/absence of metastases) and in 25 control samples were evaluated.
The profiling was performed using microarrays. Significance Analysis of Microarrays test was applied in the analysis
of microarray data (both unsupervised and supervised data analyses were performed). Validation of the obtained
results was performed using real-time qPCR. Subsequently, predicted targets for the microRNAs were searched for
in miRBase.
Results: Results of the unsupervised analysis indicate that the primary factor separating the samples is the metastasis
status. Predicted targets for microRNAs differentially expressed in the metastatic vs. non-metastatic group are mostly
engaged in cell cycle regulation, cell differentiation and DNA-damage repair. On the other hand, the supervised analysis
reveals clusters of differentially expressed microRNAs unique for the tumour type, malignancy grade and metastasis factor.
Conclusions: The most significant difference in microRNA expression was observed between the metastatic and non-
metastatic group, which suggests a more important role of microRNAs in the metastasis process than in the malignant
transformation. Moreover, the differentially expressed microRNAs constitute potential metastasis markers. However,
validation of cfa-miR-144, cfa-miR-32 and cfa-miR-374a levels in blood samples did not follow changes observed in the
non-metastatic and metastatic tumours.
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Background
Mammary tumours occur spontaneously in dog and hu-
man populations [1]. Epidemiology of this disease is
similar in both species, partly due to the dog being a
companion animal, i.e. living in similar environmental
conditions to humans. Canine and human mammary tu-
mours are hormone-dependent and usually originate
from epithelial tissue [2]. The most common histological
type of malignant mammary tumours in dogs is complex
carcinoma [3] and that of human breast cancer is invasive
ductal carcinoma [4]. Canine mammary carcinoma fre-
quently invades lymph nodes and metastasises to the
lungs [5, 6], but rarely to the bones [6, 7]. Human breast
cancer often spread to lymph nodes, lungs, bones and to
the liver [8]. Many similar oncogenes were found for
human breast cancer and canine mammary carcinoma,
for instance oncogenic microRNAs [9]. Moreover, many
changes in pathways related to mammary cancer (includ-
ing KRAS, PTEN, PI3K/AKT, WNT-beta catenin and
MAPK cascade) are common for both species [10]. All
these molecular similarities made canine mammary cancer
a good genetic model for human breast cancer [11].
Some microRNAs are up-regulated and some are down-
regulated in cancer, which suggests that microRNAs may
act as oncogenes or tumour suppressor genes [12]. Many
microRNAs are located in fragile sites (FRAs) − preferen-
tial sites of alterations (e.g. amplification or deletion) in a
genome. Hence, amplification of chromosomal regions
containing oncogenic microRNAs and/or deletion of sites
including suppressor microRNAs may lead to cancer de-
velopment [13]. When showing the connection between
microRNA expression and cancer it is also very important
to establish microRNA’s functional role. For example, p53
activates the expression of miR-34a, which then promotes
apoptosis [14]. MiR-27a inhibits the expression of the Sp
repressor ZBTB10/RINZF [15], leading to the overexpres-
sion of Sp factors and, as a consequence, to the increase of
Sp-dependent antiapoptotic and angiogenic molecules’
number, e.g. survivin and vascular endothelial growth
factor (VEGF), responsible for cancer development [16].
MiR-10b suppresses the homeobox D10 (HOXD10). Ex-
pression of HOXD10 releases the pro-metastatic gene
RHOC and results in tumour invasion and metastasis
[17]. In general, all these findings suggest that microRNAs
may serve as diagnostic and prognostic factors.
Expression profiles of a few microRNAs have been
investigated in canine mammary cancer. Von Deetzen
et al. compared the expression profiles of 16 microRNAs
(miR-136, miR-143, let-7f, miR-29b, miR-145, miR-9, miR-
10b, miR-203, miR-125b, miR-15a, miR-16, miR-21, miR-
101, miR-210, miR-194 and miR-125a) in three types of
canine mammary tumours (adenoma, non-metastasising
carcinoma, metastasising carcinoma), lymph node metas-
tases and in a normal mammary gland. One of their
results was the higher expression level of miR-210 in all
neoplastic tissues in comparison to the normal gland.
They also found that miR-29b, miR-101, miR-143, miR-
145 and miR-125a are down-regulated in metastatic sites
when compared to the primary tumours. Further, they did
not find any significant difference in miR-9, miR-10b,
miR-15a, miR-16, miR-125b, miR-136 and let-7f expres-
sion levels among the examined groups [18].
Our study is the first to identify the expression profiles
of 317 microRNAs in canine mammary tumours of dif-
ferent histological type, malignancy grade and clinical
history (presence or absence of metastases) and in a
control group (normal mammary gland samples). This




Tumour samples were collected during mastectomy per-
formed according to standard veterinary procedures.
One half of every tumour was immersed in 10% neutral
buffered formalin and stored at room temperature. The
other was immersed in RNAlater® Stabilization Solution
(Ambion, USA) and stored at −80°C. The total number
of obtained samples amounts to 171 (39 samples were
received from veterinary clinics in Warsaw (Poland), 104
samples – from the Freie Universitaet Berlin (Berlin,
Germany) and 28 samples – from the Swedish Univer-
sity of Agricultural Sciences (Uppsala, Sweden)). The
samples from Germany and Sweden were shipped to
Poland in RNAlater® Stabilization Solution on dry ice.
Radiography was used for the diagnosis of metastases
for the cases in Poland. The samples from Sweden were
obtained from dogs that died or were euthanized due to
their mammary carcinoma. This was confirmed by a
post-mortem examination or x-ray of the lungs and the
latter was based on the information from the clinician or
from the owner [19].
Tumour classification and immunohistochemistry
Histological classification of the tumours was performed
according to the World Health Organization (WHO)
Histological Classification of Mammary Tumors in the
Dog and Cat [20]. Grades of malignancy were allocated in
accordance with the Nottingham method for human breast
tumours, which is based on the assessment of three mor-
phological features: mitotic counts, nuclear pleomorphism
and tubule formation [21]. Tumoural characteristics of the
samples No. 26–144 were assessed by immunohistochemi-
cal examination of cytokeratin, vimentin, smooth muscle
actin, s100 protein and p63 protein expression.
For immunohistochemical analysis, tumour samples were
embedded in paraffin. 3-μm-thick sections of the tumours
were cut, fixed on slides and dried overnight at 37°C. After
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drying, slides were dewaxed in xylene, rehydrated in ethanol,
boiled in 0.02 M citrate buffer (pH 6.0), washed in H2O2,
washed with distilled water, washed in phosphate buffered
saline (PBS) and incubated in 1–2% bovine serum albumin.
Afterwards, sections were incubated overnight at 4°C in
primary antibodies diluted in 1–2% bovine serum albumin.
The following primary antibodies were used: Monoclonal
Mouse Anti-Human Cytokeratin, Clone MNF116, 1:50
(Dako, Agilent Technologies, USA); Monoclonal Mouse
Anti-Vimentin, Clone Vim 3B4, 1:100 (Dako); Monoclonal
Mouse Anti-Human Actin (Muscle), Clone HHF35, 1:50
(Dako); Polyclonal Rabbit Anti-S100, 1:400 (Dako) and
Monoclonal Mouse Anti-Human p63 Protein, 1:50 (Dako).
After incubation in primary antibodies, slides were washed
in PBS. Subsequently, staining was performed using EnVi-
sion™+ System-HRP (DAB) Kit (Dako). Tumour sections
were incubated in Labelled Polymer-HRP (polymer conju-
gated with horseradish peroxidase enzyme) and in 3,3`-diami-
nobenzidine (DAB) chromogen (diluted according to the
manufacturer’s protocol). After chromogen reaction, slides
were washed under cold running water, stained with haema-
toxylin and eosin, washed again under cold running water and
dehydrated in alcohol and in xylene. Coverslips on slides were
fixed using Mounting Medium (Dako). Slides with coverslips
were dried overnight at 37°C. Antigen spots were counted by
a computer-assisted image analyser (Olympus Microimage™
Image Analysis, software version 4.0 for Windows, Japan).
RNA isolation from tumour samples
RNA was isolated from tumour pieces with a diameter
of 1 cm. Each piece was washed with RNase Away Re-
agent (Ambion) and disrupted in Tissue Lyser LT (QIA-
GEN, Germany) at 50 Hz for 30 min. After disruption,
total RNA was isolated from samples using miRNeasy
Mini Kit (QIAGEN) according to the manufacturer’s
protocol. Isolated RNA was stored at −80°C. RNA
quantity and contamination with proteins and organic
compounds were examined using NanoDrop 2000
(NanoDrop, USA). RNA integrity was assessed using
Agilent 2100 Bioanalyzer (Agilent Technologies, USA).
MicroRNA microarray profiling
Samples (750 ng of total RNA) were labelled with fluores-
cent labels (examined samples with Hy3™ label − green
fluorescence, reference samples with Hy5™ label − red fluor-
escence) using miRCURY LNA™ microRNA Hi-Power
Labeling Kit, Hy3™/Hy5™ (Exiqon, Denmark) according to
the manufacturer’s protocol. The Hy3™-labelled examined
samples and Hy5™-labelled reference samples were mixed
pair-wise and hybridized on miRCURY LNA™ microRNA
Array 7th generation − hsa, mmu & rno (Exiqon) using
Tecan HS4800TM Hybridization Station (Tecan, Austria).
After hybridization, microarray slides were scanned and
stored in an ozone free environment (ozone level below
2.0 ppb). Scanning was carried out using Agilent G2565BA
Microarray Scanner (Agilent Technologies). Image analysis
was performed using ImaGene 9.0 software (BioDiscovery,
USA). Quantified signals were normalized using quantile
normalization method.
Both unsupervised and supervised analyses of data
were performed. Unsupervised analysis was carried out
without dividing samples into groups and it includes
Principal Component Analysis (PCA) and unsupervised
hierarchical clustering (two-way hierarchical clustering).
For supervised analysis, samples were divided into
groups according to three factors: tumour type, malig-
nancy grade, and metastasis. Unsupervised and super-
vised analyses of data were performed using BRB-
ArrayTools, Version 4.3.2 (developed by Dr. Richard
Simon and BRB-Array Tools Development Team). For
the unsupervised analysis, the variances of microRNAs
were calculated using Excel’s VAR.S function. For the
supervised analysis, Significance Analysis of Microarrays
(SAM) test, which sets estimate of False Discovery Rate
for multiple testing, was applied. Results of the analyses
are shown on heat maps and 3D–PCA plots. Heat maps
were drawn using BRB-ArrayTools, 3D–plots − using
Python programming version 3.4 [22] with the Matplotlib
version 1.4.3 data visualization package [23]. To make heat
maps, the normalized expression values of microRNAs
were standardized by the Excel’s STANDARDIZE func-
tion, then on the heat map an expression level below the
mean was represented by green colour and an expression
level above the mean was represented by red colour.
Validation of microarray results
For validation of microarray results were selected micro-
RNAs showing more than 2-fold up- or down-regulation
(LogFoldChange above +1.0 or below −1.0), statistically
significant regulation (adjusted p-values <0.05) and aver-
age array signal intensity of the probes well above the
background (in the range 7.5–14.5). The real-time quanti-
tative PCR (RT-qPCR) method was applied for the valid-
ation. cDNA synthesis was carried out using Universal
cDNA Synthesis Kit (Exiqon) according to the manufac-
turer’s protocol in Eppendorf MasterCycler Personal ther-
mal cycler (Eppendorf, Germany). RT-qPCR was
performed using LNA™ PCR primer sets (Exiqon) and Exi-
LENT SYBR® Green master mix (Exiqon) according to the
manufacturer’s protocol in Stratagene Mx3005P qPCR
System (Agilent Technologies). Target sequences for the
primer sets are shown in Additional file 1. The results of
RT-qPCR were analysed using GenEx 6 software (Exiqon).
Validation of selected targets for microRNAs deregulated
in metastatic canine mammary cancer
The following 17 genes were selected for validation of pre-
dicted targets for microRNAs deregulated in metastatic
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canine mammary cancer: CDC6, CCNE1, MYBL2,
PDCD10, ERBB2IP, SON, STK4, CDC27, PRC1, CDC37,
TTK, SKIL, BUB3, SPIN1, EEF2, ACTB and HPRT. The
RT-qPCR method was applied for the validation. cDNA
synthesis was performed using High Capacity RNA-to-
cDNA Kit (Life Technologies, USA) according to the
manufacturer’s protocol in MasterCycler® pro PCR System
(Eppendorf). RT-qPCR was carried out using Oligo.pl
primer sets (Oligo, Poland) and SYBR® Select Master Mix
(Life Technologies) according to the manufacturer’s proto-
col in Stratagene Mx3005P qPCR System (Agilent Technolo-
gies). The primers’ sequences are shown in Additional file 2.
The results of RT-qPCR were analysed using GraphPad
Prism 6 (GraphPad Software, USA).
Blood samples
Whole blood samples were obtained from 50 female dogs
diagnosed with canine mammary tumours. All these sam-
ples were collected during cephalic vein catheterization
prior to mastectomy in the Department of Small Animal
Diseases with Clinic (Faculty of Veterinary Medicine,
Warsaw University of Life Sciences) and in two private
veterinary clinics in Warsaw except a bitch that was not
qualified for surgery due to lung metastasis. From this
patient, blood was taken from the cephalic vein by
catheterization before euthanasia. In brief, 38 dogs with
non-metastatic tumours (10 benign and 28 malignant
tumours in various stages) and 12 dogs with tumour
recurrence or metastasis were qualified for this study.
Detailed characteristics of all the samples are included in
Additional file 3.
For a control group, 12 blood samples were collected
from healthy bitches during routine veterinary examin-
ation before ovariohysterectomy in two private veterin-
ary clinics in Warsaw. Patients with possible diseases
and pathological stages, which might influence the study
and its results, were excluded.
All dogs underwent standard clinical examination before
the procedure, including: the patient’s history, complete
physical examination, documentation of tumour charac-
teristics, haematological examination, serum biochemistry
profile and three thoracic radiographic projections – right,
left lateral and dorsoventral. Four millilitres of blood were
collected into 6 ml K2EDTA plastic tubes (BD Vacutainer)
and centrifuged on the same day at 4000 RPM for 15 min
at 4 °C. Plasma was next carefully aspirated and trans-
ferred into a new tube and centrifuged again under the
same conditions. Finally, the supernatant was transferred
into a new tube and stored at −80 °C until RNA isolation.
RNA isolation from plasma samples
MicroRNA was extracted using QIAamp Circulating
Acid Kit (QIAGEN) according to the manufacturer’s
protocol for 1 ml of plasma. In the last step of the
procedure, microRNA was suspended in 40 μl of elution
buffer AVE. The quantity of microRNA was measured
using NanoDrop Spectrophotometer (NanoDrop Tech-
nologies, USA) whereas RNA quality and integrity were
assessed using BioAnalyzer (Agilent, USA). Only sam-
ples with a RIN > 8 were taken to the further study.
cDNA synthesis and quantitative real time PCR for plasma
microRNAs
Four commercially available microRNA LNA PCR primer
sets (cfa-miR-144, cfa-miR-32, cfa-miR-374a and hsa-miR-
1246 (Exiqon)) were selected as metastasis-specific and
used to evaluate microRNA levels in each plasma sample.
Additionally, four microRNAs were chosen as controls
(according to Blondal et al.) for all the samples to investi-
gate possible haemolysis and erythrocyte contamination,
which might alter microRNA levels in samples [24]. Two
microRNAs affected (hsa-miR-425-5p and hsa-miR-486-
3p) and two non-affected by haemolysis (hsa-miR-744-5p
and hsa-miR-340-5p) were selected [25]. However, in the
final calculations, the most sensitive and detectable micro-
RNAs in all the samples were used (i.e. hsa-miR-486-3p
and hsa-miR744). Target sequences for the primer sets are
shown in Additional file 4.
The formula proposed by Blondal et al. identifies haemoly-
sis based on the value obtained by substracting dCT hsa-
miR-486-3p from dCT hsa-miR-744. Samples with a ddCT
>5 are considered as haemolysed and samples with a ddCT
between 7 and 8 are considered as strongly haemolysed [24].
cDNA synthesis was performed using Universal cDNA
Synthesis Kit (Exiqon) according to the manufacturer’s
protocol in Eppendorf Master Cycler Personal thermal
cycler (Eppendorf, Germany). Samples were further
frozen and stored at −20 °C. The synthetized cDNA was
diluted 1:40 and used within 24 h for qRT-PCR carried
out using ExiLENT SYBR® Green master mix (Exiqon).
10 μl of a reaction mixture consists of 5 μl of PCR Mas-
ter Mix, 1 μl of PCR primer mix and 4 μl of diluted
cDNA template. Each reaction was run in triplicate on a
96-well plate using Stratagene Mx3005P qPCR System
(Agilent Technologies). Results of qRT-PCR were calcu-
lated using the comparative Ct method [26] and statisti-
cally analysed by Prism version 6.00 software (GraphPad
Software, USA). An unpaired, non-parametric Mann-
Whitney test was applied to compare the difference of
microRNAs expression between the non-metastatic and
metastatic group. Statistical significance was defined as
p-value <0.05. Due to the magnitude and range of ob-
served results, the data was log-transformed for analysis.
Results
Sample characteristics
A total of 171 samples were included in this study, 146
of which were canine mammary tumours (30 benign
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tumours and 116 malignant tumours) and 25 were nor-
mal mammary gland samples. The group of malignant
tumours consisted of 115 carcinoma samples and one
carcinosarcoma case. The malignant tumours were of
different histological subtypes (histological classification
of the samples is included in Table 1), grades of malig-
nancy (grade I − 27 samples, grade II − 29 samples,
grade III − 27 samples, unknown − 33 samples) and
clinical histories (presence of metastases − 58 samples,
absence of metastases − 49 samples, unknown − 9 sam-
ples). Detailed characteristics of all the samples included
in the study are shown in Additional file 5.
MicroRNA microarray analysis
The technical data quality assessment showed that the
sample labelling with Hy3™ and Hy5™ fluorescent labels
was successful as all capture probes for the control
spike-in oligonucleotides produced signals in the
expected range. Subsequently, a total of 317 microRNAs
were used for threshold filtering and 122 probes were
discarded by the filtering procedure. The obtained num-
ber of present calls for the samples was within the
expected range.
Both unsupervised and supervised analyses of data
were performed. Unsupervised analysis includes Princi-
pal Component Analysis and unsupervised hierarchical
clustering (two-way hierarchical clustering). Principal
Component Analysis was conducted to reduce the di-
mensions of large data sets and to explore the naturally
arising sample classes based on the expression profile.
By including the top 50 microRNAs with the largest
variation across all the samples, we obtained an overview
of how the samples clustered based on this variance.
This led to the separation of the samples in different re-
gions of a PCA plot corresponding to their biology. The
result of PCA is presented as a 3D–PCA plot (Fig. 1).
The 3D–PCA plot reveals the distinct sample clusters
for metastatic tumours, non-metastatic tumours and the
control group. Unsupervised hierarchical clustering
(two-way hierarchical clustering of microRNAs and sam-
ples) was performed using the complete-linkage method
together with the Euclidean distance measure. The result
of this analysis is shown in Fig. 2. In general, the un-
supervised analysis shows that the primary factor separ-
ating the samples is the metastatic status.
For supervised analysis, samples were divided into
groups according to three factors: tumour type, malig-
nancy grade and metastatic status (the histological sub-
type was not used as a factor for any analysis because of
a large number of groups with widely varying sizes). Sig-
nificance Analysis of Microarrays test for each of the
three factors was performed. For the tumour type factor,
a subset of 123 microRNAs was identified out of the
total of 195 analysed microRNAs that are significantly
Table 1 Histological classification of the tumour samples
(summary)
Control/Tumour type Histological type No. Σ
Control 25 25
Benign tumour Simple adenoma 3 30
Complex adenoma 16
Atypical adenoma 1
Atypical simple adenoma 1
Atypical complex adenoma 1
Basaloid adenoma 1
Atypical papilloma 3
Benign mesenchymal tumour 2
Benign mixed tumour 1
Simple adenoma + Complex
adenoma
1
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Fig. 1 3D–PCA plot − unsupervised analysis. PCA performed on all the samples and on the top 50 microRNAs with the highest standard
deviation. The normalized log-transformed Hy3 values were used for the analysis. The features were shifted to be zero centred, (i.e. the mean
value across samples was shifted to 0) and scaled to have unit variance (i.e. the variance across samples was scaled to 1) before the analysis. PCA
plot reveals the distinct sample clusters for metastatic tumours, non-metastatic tumours and the control group
Fig. 2 Heat map − unsupervised hierarchical clustering. Clustering performed on all the samples and on the top 50 microRNAs with the highest
standard deviation. The normalized log-transformed Hy3 values were used for the analysis. The colour scale illustrates the relative expression level
of a microRNA across all samples: green colour represents an expression level below the mean and red colour represents an expression level
above the mean. Legend: n.a. − data not available
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differentially expressed in different groups (the controls,
benign tumours and malignant tumours). Of these 123
microRNAs, 84 miRNAs were down-regulated in the
malignant tumour group in comparison with the control
group, seven miRNAs were up-regulated in the malig-
nant group compared to the controls, 20 miRNAs were
down-regulated in the malignant tumours when com-
pared to the benign tumour group, three miRNAs were
up-regulated in the malignant group in comparison with
the benign group, eight miRNAs were up-regulated in
the benign tumours compared to the controls and one
miRNAs was down-regulated in the benign tumour
group when compared to the controls. The results of
this analysis are shown in Additional file 6. One of the
samples used in this analysis was marked as ‘malignant
+ hyperplasia’, as it was classified as a mixed histological
type. The microRNA profile of this sample was mostly
similar to the malignant group, because the specimen
included probably the malignant part of a tumour as the
main component. For the grade of malignancy, 131
differentially expressed microRNAs were identified
(Additional file 7) in the following groups: grade I, grade
II and grade III (including 13 miRNAs down-regulated
in the grade II group when compared to the grade I
group, 95 miRNAs up-regulated in the grade III group
in comparison with the grade II group, one miRNAs
down-regulated in the grade III group when compared
to the grade I group, ten miRNAs down-regulated in the
grade III group in comparison with the grade II group,
ten miRNAs up-regulated in the grade III group when
compared to the grade I group and two miRNAs up-
regulated in the grade II group compared to the grade I
group); and for the metastasis factor − 124 miRNAs
(Additional file 8) in the metastatic and non-metastatic
group (including 98 miRNAs down-regulated and 26
miRNAs up-regulated in the metastatic group in com-
parison with the non-metastatic group). In general, the
most distinct differences in microRNA profiles are be-
tween the control and malignant group for the tumour
type factor (microRNAs mostly down-regulated in the
malignant group) and between the metastatic and non-
metastatic group for the metastasis factor (microRNAs
mostly down-regulated in the metastatic group). To
enable quick visual identification of microRNAs display-
ing large-magnitude changes that are also statistically
significant, the expression data were plotted in heat
maps (tumour type − Fig. 3, grade of malignancy − Fig. 4,
metastasis − Fig. 5). For these microRNAs, PCA plots
were also performed (tumour type − Fig. 6, grade of ma-
lignancy − Fig. 7, metastasis − Fig. 8).
Validation of microarray results
The following ten microRNAs were selected for valid-
ation of microarray results: cfa-let-7c, cfa-miR-10b, cfa-
miR-26a, cfa-miR-26b, cfa-miR-29c, cfa-miR-30a, cfa-
miR-30b, cfa-miR-30c, cfa-miR-148a and cfa-miR-299.
Average array signal intensity of the probes, p-values
and fold changes for these microRNAs can be found in
Additional file 8. The validation was performed on 47
samples including five controls, five benign tumours, ten
malignant non-metastatic tumours and 27 malignant
metastatic tumours. The validation results are shown in
Table 2. All the validated microRNAs are significantly
differentially expressed among the examined groups.
However, the distinction among the expression levels of
these microRNAs in the groups is not as marked as in
the microarray analysis.
Validation of selected targets for microRNAs deregulated
in metastatic canine mammary cancer
For validation of predicted targets for microRNAs deregu-
lated in metastatic canine mammary cancer were selected
14 genes, which expression differ in the metastatic and
non-metastatic group (CDC6, CCNE1, MYBL2, PDCD10,
ERBB2IP, SON, STK4, CDC27, PRC1, CDC37, TTK, SKIL,
BUB3 and SPIN1). Three housekeeping genes (EEF2,
ACTB, and HPRT) were used as controls. The function of
selected target genes and the list of microRNAs, which
regulate their expression, are included in Additional file 9.
The validation was performed on 20 samples (ten malig-
nant non-metastatic tumours and ten malignant metastatic
tumours). The validation results are shown in Fig. 9 and in
Table 3. Klopfleisch et al. found the higher expression of
CDC6, CCNE1, MYBL2, PDCD10, ERBB2IP, SON, STK4,
CDC27, PRC1, CDC37, TTK, SKIL, BUB3 and SPIN1 in
metastatic canine mammary cancer in comparison with
non-metastatic canine mammary cancer [27]. Our results
show the statistically significant up-regulation of CDC6,
CCNE1, MYBL2, ERBB2IP, SON, STK4, CDC27, PRC1,
CDC37, TTK and SKIL in the metastatic group when com-
pared to the non-metastatic group.
Validation of selected microRNAs levels in plasma
samples as cancer markers
Three of the most down-regulated miRNAs in the meta-
static group, revealed in tumour samples in our microarray
analysis (cfa-miR-144, cfa-miR-32 and cfa-miR-374a), and
hsa-miR-1246, known for its deregulation in plasma from
human breast cancer patients [28], were chosen for the
evaluation in plasma samples. Thirty-five out of fifty exam-
ined plasma samples were derived from the same dogs
which tumours were used for the microarray analysis.
RT-PCR results for these four microRNAs in plasma
demonstrated no significant differences in expression
level between the metastatic and non-metastatic group.
Moreover, plasma levels of these microRNAs did not dif-
fer significantly when compared to those in healthy dogs.
P-values vary from 0.6 in cfa-miR-144, 0.89 in cfa-miR-
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32, to 0.27 in cfa-miR-374a in contrast to <1e−07 in
tumour samples and fold change 4.74, 3.54 and 3.24,
respectively. P-value for hsa-miR-1246 amounts to 0.67.
The results are shown in Fig. 10.
Evaluation of haemolysis risk in plasma samples
Results of hsa-miR-744-5p and hsa-miR-486-3p expres-
sion subtraction revealed that five out of 62 plasma sam-
ples show a minor risk of erythrocyte contamination
(ranging from 5.01 to 5.7). However, these samples were
not excluded from the analysis due to the lack of variation
in the levels of investigated microRNAs when compared
to the other samples and also occurrence of microRNAs,
which are not characteristic for red blood cells.
Discussion
The results of this study are largely in line with the find-
ings of von Deetzen’s group [18]. We also found the
significant down-regulation of miR-29b, miR-101, miR-
143, miR-145 and miR-125a in a metastatic group in
comparison with benign tumours. Higher expression of
miR-210 in neoplasms than in a control group and up-
regulation of miR-21 in non-metastasising tumours
when compared to normal mammary tissue were similar
in the two studies as well. However, there are some dis-
crepancies between our findings and those of von Deet-
zen’s group. For instance, our results show that the
expression of miR-203 is down-regulated in benign tu-
mours in comparison with a control group. Von Deetzen
et al. found that the expression level of this microRNA
is higher in adenoma when compared to normal mam-
mary tissue. Our findings revealed a gradual decrease in
miR-10b, miR-125b, miR-136 and let-7f expression levels
from normal mammary tissue, through benign tumours
and non-metastatic malignant tumours, to metastatic
tumours. Von Deetzen’s group observed no significant
Fig. 3 Heat map − tumour type. The scaled expression of the differentially expressed microRNAs for 171 samples and the relationship among the
samples in terms of microRNAs found to be differentially expressed for the tumour type factor; Significance Analysis of Microarrays (SAM) test; the
colour scale illustrates the relative expression level of a microRNA across all samples: green colour represents an expression level below the mean
and red colour represents an expression level above the mean. The most distinct differences in microRNA profile are between the control and
malignant group − microRNAs mostly down-regulated in the malignant group
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Fig. 4 Heat map − grade of malignancy. The scaled expression of the differentially expressed microRNAs for 111 samples and the relationship among
the samples in terms of microRNAs found to be differentially expressed for the malignancy grade factor; Significance Analysis of Microarrays (SAM) test;
the colour scale illustrates the relative expression level of a microRNA across all samples: green colour represents an expression level below the mean
and red colour represents an expression level above the mean. MicroRNAs are mostly up-regulated in the grade III group in comparison with the grade
II group
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difference in the expression profiles of these microRNA
among the examined tissues [18]. The discrepancies
between the two studies may be caused by the fact that
one microRNA can have many target genes and some
tumours with the same histopathological diagnosis can
be the result of different derangements of cellular
pathways. Among the microRNAs for which the findings
of the two groups differ, we found target genes in canine
mammary cancer for miR-10b, miR-125b and let-7f (the
targets together with their function are included in
Additional file 9). The target genes for these microRNAs
are engaged in cell cycle regulation, cell differentiation
Fig. 5 Heat map − metastasis. The scaled expression of the differentially expressed microRNAs for 107 samples and the relationship among the
samples in terms of microRNAs found to be differentially expressed for the metastasis factor; Significance Analysis of Microarrays (SAM) test; the
colour scale illustrates the relative expression level of a microRNA across all samples: green colour represents an expression level below the mean
and red colour represents an expression level above the mean. MicroRNAs are mostly down-regulated in the metastatic group
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and receptors function. Up-regulation of these genes
leads to deregulation of cellular processes and may be a
reason for cancer development. However, the discrepan-
cies between the results of this work and the findings of
von Deetzen’s group may be caused by the differences in
the sample types and in the data analysis used in
these two studies. Von Deetzen et al. performed their
experiments on three types of canine mammary tu-
mours (adenoma, non-metastasising carcinoma and
metastasising carcinoma) and analysed all these types
separately. We used many histological types of be-
nign, malignant non-metastatic and malignant meta-
static tumours and combined together the histological
types in the analysis of data.
Fig. 6 3D–PCA plot − tumour type. PCA plot performed on 171 samples and 123 differentially expressed microRNAs for the tumour type factor;
Significance Analysis of Microarrays (SAM) test. PCA plot reveals the distinct sample clusters for malignant tumours, benign tumours and the
control group
Fig. 7 3D–PCA plot − grade of malignancy. PCA plot performed on 111 samples and 131 differentially expressed microRNAs for the malignancy
grade factor; Significance Analysis of Microarrays (SAM) test
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Predicted targets for microRNAs deregulated in
metastatic canine mammary cancer
Klopfleisch et al. compared the global gene expression of
metastatic and non-metastatic canine mammary carcin-
omas. They found 1011 differentially expressed genes, 744
of which were up-regulated and 267 were down-regulated.
Among up-regulated genes were those engaged in cell cycle
regulation, protein folding, proteasomal degradation and
matrix modulation whereas among down-regulated ones
where those which play roles in differentiation, growth fac-
tor pathways and actin organization [27]. We searched in
miRBase [29] for predicted targets of microRNAs that we
found differentially expressed in metastatic when compared
to non-metastatic canine mammary cancer. Subsequently,
we checked if these targets were among the genes deregu-
lated in metastatic mammary cancer (described by
Klopfleisch et al. [27]) and whether the expression profiles
correlated i.e. under-expression of a microRNA suggests
over-expression of its target gene and vice versa. Conse-
quently, we found 44 microRNAs with predicted targets in
metastatic canine mammary cancer. Forty-three of
these microRNAs are down-regulated whereas one is
up-regulated. A list of these 44 microRNAs together
with their targets’ names and function is included in
Additional file 9. Among the targets are mostly genes
engaged in cell cycle regulation, cell differentiation
and DNA-damage repair, which are all key processes
in tumorigenesis.
Fig. 8 3D–PCA plot − metastasis. PCA plot performed on 107 samples and 124 differentially expressed microRNAs for the metastasis factor;
Significance Analysis of Microarrays (SAM) test. PCA plot reveals the distinct sample clusters for metastatic tumours and non-metastatic tumours









let-7c < 1e-07 0.02892256 2.066592593 1.551592593 0.885092593 0
miR-26b < 1e-07 0.00001507 1.56060648 0.04060648 −0.57989352 −1.02131944
miR-26a < 1e-07 0.00003571 1.11365741 0.50621296 −0.58834259 −1.03152778
miR-30a 3.00E-07 0.00367713 −0.09936889 0.71563112 0.08413112 −0.70039334
miR-148a 3.00E-07 0.04282469 0.32479167 0.55945833 −0.50670833 −0.37754167
miR-29c 5.00E-07 0.00019157 0.79212037 0.30412037 −0.25387963 −0.84236111
miR-30c 2.70E-06 0.00133947 0.2615463 0.59621296 0.0315463 −0.88930556
miR-299 5.40E-06 0.04632324 1.899074074 0.425074074 2.399074074 0
miR-10b 6.00E-06 0.01635353 0.9961408 0.07058524 −0.46735921 −0.59936683
miR-30b 1.74E-05 0.00557426 0.61328913 0.43528913 −0.40171087 −0.6468674
one-way ANOVA p-values for microarray results and RT-qPCR results; RT-qPCRs performed for 10 microRNAs on 47 samples (5 controls, 5 benign tumours, 10
malignant non-metastatic tumours and 27 malignant metastatic tumours)
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Common microRNAs deregulated in canine mammary
cancer and human breast cancer
Seventeen out of all the microRNAs, which we found
deregulated in canine mammary cancer, were also previ-
ously described as deregulated in human breast cancer.
Twelve of them (miR-10b, miR-15a, miR-19a, miR-26b,
miR-30a, miR-30c, miR-125a, miR-125b, miR-148a, miR-
148b, miR-195 and miR-320) are down-regulated both in
dogs and in humans whereas one (miR-494) is up-
regulated in both species and four (miR-29a, miR-181a,
miR-196a and miR-374a) are down-regulated in dogs
but up-regulated in humans. Target genes of these 17
microRNAs are mostly engaged in cell cycle regulation,
apoptosis and angiogenesis [30–45]. A full list of com-
mon microRNAs deregulated in canine mammary can-
cer and human breast cancer together with the target
genes and their function is shown in Table 4.
The discrepancies in the expression levels of miR-29a,
miR-181a, miR-196a and miR-374a between dogs and
humans may be caused by other target genes having a
Fig. 9 Heat map − selected targets for microRNAs deregulated in
metastatic canine mammary cancer. The scaled expression of
CDC6, CCNE1, MYBL2, PDCD10, ERBB2IP, SON, STK4, CDC27, PRC1,
CDC37, TTK, SKIL, BUB3 and SPIN1. The analysis performed on ten
malignant non-metastatic tumours and ten malignant metastatic
tumours. Statistical analysis was made on Ct values normalized
with a housekeeping gene; one-way ANOVA followed by Tukey’s
HSD post hoc tests. Legend: log2 FC – log base 2 from fold
change, * – p value <0.05, ** – p value <0.01, *** – p value <0.001
Table 3 Validation of selected targets for microRNAs
deregulated in metastatic canine mammary cancer
Gene Mean difference Lower Upper p-value
CDC6 1.662166667 0.296219571 3.028113763 0.014739925
CCNE1 1.805333334 0.698148282 2.912518385 0.00111525
MYBL2 1.469333333 0.095498643 2.843168024 0.034267
PDCD10 0.315 −1.466393723 2.096393723 0.899858502
ERBB2IP 1.863333333 0.181873946 3.544792721 0.027609459
SON 1.691333333 0.149694553 3.232972114 0.029382504
STK4 2.356333333 0.708656745 4.004009921 0.004014445
CDC27 2.316333334 0.684213855 3.948452812 0.004297527
PRC1 3.368333333 1.644772232 5.091894434 0.000132898
CDC37 3.250833333 1.273918023 5.227748644 0.001019454
TTK 2.8475 0.856445769 4.838554231 0.004013127
SKIL 2.291666667 0.327926258 4.255407076 0.019726893
BUB3 0.976666667 −0.467839044 2.421172377 0.232448632
SPIN1 1.248333333 −0.448209573 2.944876239 0.180817071
The analysis performed on ten malignant non-metastatic tumours and ten
malignant metastatic tumours. Statistical analysis was made on Ct values
normalized with a housekeeping gene; one-way ANOVA followed by Tukey’s
HSD post hoc tests
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stronger influence on canine mammary cancer than hu-
man breast cancer development, i.e. other genes than
those reported in the literature about breast cancer [34,
40, 42, 44]. We found target genes for miR-29a, miR-
181a and miR-374a in the dogs’ mammary cancer. The
results are included in Table 5.
Up-regulation of the target genes for these microRNAs
leads to a derangement of cell cycle control and cell dif-
ferentiation and, as a consequence, plays a role in the
onset of cancer and, subsequently, in the metastatic pro-
gression [27]. However, the differences in the expression
profiles of miR-29a, miR-181a, miR-196a and miR-374a
may be due to the presence of normal mammary stromal
cells in the examined tumour samples, what is some-
times difficult to avoid. Stroma of the normal human
mammary gland includes myofibroblasts [46] and that of
the dog does not include them [47], so this distinction
may be a reason for the microRNA discrepancies be-
tween dogs and humans. A role of these microRNAs in
myofibroblast differentiation was previously described
[48–50].
Validation of selected microRNAs levels in plasma
samples as cancer markers
While deregulated microRNAs in tissue samples regulate
known targets involved in tumour development and
Fig. 10 Expression of selected microRNAs in plasma samples from dogs with non-metastatic and metastatic tumours. Relative expression of cfa-miR-144,
cfa-miR-32 cfa-miR-374a and hsa-miR-1246 in plasma samples from dogs with non-metastatic and metastatic tumours. The statistical analysis was performed
using Prism version 5.00 software (GraphPad Software, USA). An unpaired, non-parametric Mann-Whitney test was applied. Values are mean ± SD
Table 4 Common microRNAs deregulated in canine mammary cancer and human breast cancer [30–45]
microRNA Canine mammary cancer Human breast cancer Target genes Targets’ function
miR-10b down-regulated down-regulated BUB1, PLK1, CCNA2 cell cycle regulation
miR-15a down-regulated down-regulated CCNE1 cell cycle regulation
miR-19a down-regulated down-regulated Fra-1 proto-oncogene inducing macrophage
polarization
miR-26b down-regulated down-regulated SLC7A11 apoptosis
miR-29a down-regulated up-regulated Col4a2, Spry1, Timp3 antiangiogenic
miR-30a down-regulated down-regulated MTDH angiogenesis
miR-30c down-regulated down-regulated KRAS signalling
miR-125a down-regulated down-regulated HER2, HER3 epidermal growth factor
receptors
miR-125b down-regulated down-regulated HER2, HER3 epidermal growth factor
receptors
miR-148a down-regulated down-regulated ERBB3 growth factor
miR-148b down-regulated down-regulated ITGA5, ROCK1, PIK3CA, NRAS, CSF1
miR-181a down-regulated up-regulated ATM stress-sensor kinase
miR-195 down-regulated down-regulated CCNE1 cyclin
miR-196a down-regulated up-regulated ANXA1 apoptosis
miR-320 down-regulated down-regulated TRPC5, NFATC3
miR-374a down-regulated up-regulated WIF1, PTEN, WNT5A negative regulators of the Wnt/
β-catenin signalling cascade
miR-494 up-regulated up-regulated PTEN negative regulator of the Akt/
PKB signalling pathway
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metastasis, circulating microRNAs might play a role as
stable, specific biomarkers for cancer diagnosis and
prognosis [51]. Interestingly, Chen et al. showed that the
unique signature of microRNAs in blood samples might
follow the same pattern as in tumours [52]. However,
this trend has not been observed in our study. The PCR
analysis showed no significant differences in the expres-
sion of selected miRNAs between the metastatic and
non-metastatic group. Such dissimilarity between the
obtained results from tumour and plasma samples can
be challenging to elucidate, as the mechanism of micro-
RNA release into the blood is not fully understood yet.
Steudemann et al. pointed out that microRNAs might be
released not only by pathologically changed tissue, but
also by other organs in the body modifying its final ex-
pression in blood samples [53]. Moreover, a recently dis-
covered role of haemolysis in altering plasma levels of
microRNAs put an ongoing question regarding other
factors with a similar impact [54].
Many factors may play a role in the analysis of plasma
microRNA levels. Due to the variety of conditions and
used techniques, the process of raw data normalization
might be critical to obtain reliable results. To date, there
is no endogenous control for the evaluation of circulat-
ing microRNAs. An ideal candidate should remain stable
in both healthy and affected individuals and resistant to
external factors. Several studies proposed miR-16 as a
potential housekeeping gene in human studies. However,
the expression of this microRNA was down-regulated in
the malignant group in our microarray data and there-
fore it could not be applicable for the evaluation of
plasma samples [55, 56]. As a result, we used the expres-
sion of a synthetic RNA spike-in (UniSp6) for the in-
ternal normalization of microRNA level. The average Ct
values within groups were detectable in all the investi-
gated samples, however, did not show any differences
between the groups.
Conclusions
In summary, the microRNA profiling of canine mammary
cancer has identified microRNAs that are differentially
expressed according to the tumour type, malignancy grade
and metastasis factor regardless of the tumours’ histo-
logical type. The most significant difference in microRNA
expression has been found between the metastatic and
non-metastatic group. These results are very interesting
because, firstly, they suggest that microRNAs regulate
mostly the metastasis process (not the malignant trans-
formation) and, secondly, they may constitute molecular
markers of metastasis. This is of great predictive import-
ance for the course of a disease because some histopatho-
logically identical malignant tumours have a different
clinical outcome. Moreover, due to the microRNA profile
similarities between canine mammary cancer and human
breast cancer, metastasis biomarkers for dogs can also be
further examined as useful for humans.
Additional files
Additional file 1: Target sequences for validation primer sets – microarray
results. (XLSX 43 kb)
Table 5 Predicted targets for microRNAs differently deregulated in canine mammary cancer from human breast cancer
microRNA Metastatic canine
mammary cancer
Target gene Metastatic canine
mammary cancer
Gene’s name Gene’s function
cfa-miR-29a down-regulated PARD3B up-regulated Par-3 family cell polarity regulator beta cell cycle regulation
cfa-miR-181a down-regulated RAD21 up-regulated RAD21 homolog (S. pombe) cell cycle regulation,
DNA-damage repair,
cell differentiation
BCLAF1 up-regulated BCL2-associated transcription factor 1 cell differentiation
PRKAA1 up-regulated protein kinase, AMP-activated, alpha 1
catalytic subunit
cell differentiation








LBR up-regulated lamin B receptor receptor, cell adhesion
cfa-miR-374a down-regulated SPIN1 up-regulated spindlin 1 cell cycle regulation
BUB3 up-regulated BUB3 mitotic checkpoint protein cell cycle regulation, cell
cycle checkpoint
RAD21 up-regulated RAD21 homolog (S. pombe) cell differentiation, cell cycle
regulation, DNA-damage repair
SKIN up-regulated SKI-like oncogene cell differentiation
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Additional file 2: Primers’ sequences for selected targets of microRNAs
deregulated in canine mammary cancer. (XLSX 46 kb)
Additional file 3: Characteristics of the plasma samples. Legend: x − the
factor does not concern the sample, − − the malignancy grade factor does
not concern the sample (for benign tumours), [] – samples derived from the
same dogs which tumours were used for microarray analysis. (XLS 42 kb)
Additional file 4: Target sequences for validation primer sets – plasma.
(XLSX 41 kb)
Additional file 5: Characteristics of the tumour samples. Legend: x − the
factor does not concern the sample, − − the malignancy grade factor does
not concern the sample (for benign tumours), empty spaces − data not
available. (XLSX 32 kb)
Additional file 6: Differentially expressed microRNAs for the tumour
type factor. Significance Analysis of Microarrays (SAM) test and one-way
ANOVA test. Legend: avg. Hy3 − average array signal intensity of the
probes, d(i) − observed relative difference, (Ctrl) − control, (Benign) − benign
tumour, (Mal) − malignant tumour, FDR - false discovery rate. (XLSX 62 kb)
Additional file 7: Differentially expressed microRNAs for the malignancy
grade factor. Significance Analysis of Microarrays (SAM) test and one-way
ANOVA test. Legend: avg. Hy3 − average array signal intensity of the
probes, d(i) − observed relative difference, FDR − false discovery rate.
(XLSX 63 kb)
Additional file 8: Differentially expressed microRNAs for the metastasis
factor. Significance Analysis of Microarrays (SAM) test and one-way ANOVA
test. Legend: avg. Hy3 − average array signal intensity of the probes, d(i) −
observed relative difference, (No) − non-metastatic tumour, (Yes) − metastatic
tumour, FDR − false discovery rate. (XLSX 69 kb)
Additional file 9: Predicted targets for microRNAs deregulated in
metastatic canine mammary cancer. (XLSX 21 kb)
Abbreviations
FRAs: Fragile sites; HOXD10: homeobox D10; miRNA: microRNA;
PBS: Phosphate buffered saline; PCA: Principal Component Analysis; RT-
qPCR: Real-time quantitative PCR; SAM: Significance Analysis of Microarrays;
VEGF: Vascular endothelial growth factor; WHO: World Health Organization
Acknowledgements
MicroRNA array services were performed by Exiqon A/S Company (Denmark).
Tumour samples were provided by Eva Hellmén, Robert Klopfleisch, Joanna
Mucha, Mariusz Mikow, Slawomir Gizinski and by the following veterinary
clinics in Warsaw: Multiwet, Elwet, Kabackie Centrum Weterynarii, Lecznica
dla Zwierząt - pl. Hallera 6a, Bolilapka, Bemowo and Arka. Blood samples
were provided by the Department of Small Animal Diseases with Clinic
(Faculty of Veterinary Medicine, Warsaw University of Life Sciences) and by
two veterinary clinics – Multiwet and Elwet.
Funding
This study was supported by the grant No. 2011/03/B/NZ5/05299 from the
National Science Centre (Poland). The authors declare that the funding body
has had no role in the design of the study and collection, analysis, and
interpretation of data and in writing the manuscript.
Availability of data and materials
The data generated and analysed during the current study are included in
this published article, its supplementary information files and available in the
Gene Expression Omnibus (GEO) repository (the accession number: Series
GSE103093).
Authors’ contributions
MB and AR performed the literature search. MB, AR and MK prepared the
manuscript. MB, AR and BT performed RT-qPCR experiments. KMS and AOG
performed statistical analysis of the microarray data. AR, MB and BT performed
statistical analysis of RT-qPCR data. MB, AR, MK, KU, KW, JS, JM, MM and SG
performed analysis and interpretation of data. RK, EH and ID performed
histopathological analysis and classification of the tumours. MK conceived and
designed the study. All authors read and approved the final manuscript. All
authors agreed to be accountable for all aspects of the work in ensuring that
questions related to the accuracy or integrity of any part of the work
are appropriately investigated and resolved.
Ethics approval and consent to participate
Poland: The dogs’ owners in Poland gave oral permission for the use of their
animals’ tissue and blood samples for this work. Tissue sampling in Poland
was approved by the III Local Ethical Committee (approval No. 8/2012,
17.01.2012) of the Warsaw University of Life Sciences. Blood samples in Poland
were collected according to the Polish legal act concerning experiments
performed on animals (Ustawa o doświadczeniach na zwierzętach z dnia 21
stycznia 2005 r. (Dz. U. z 2005 r. Nr 33, poz. 289 z późn.zm.)), no written approval
of the study by the Local Ethical Committee was required. Sweden: The dogs’
owners in Sweden signed a written agreement for a post-mortem examination
of the dogs and sampling of the tumours for scientific purposes. In Sweden,
there were no regulations concerning ethical approval of experiments performed
on animals at the time of the tumour sampling (1985–1987). Germany: The dogs’
owners in Germany gave oral permission for the use of their animals’ tissue
samples for scientific purposes. Tissue sampling in Germany was performed with
the approval of animal welfare authorities of the Veterinary College of the Freie
Universitaet Berlin. Surgical excision of tumour biopsies was part of the tumour
treatment according to the state of the art treatment and solely to improve the
animals’ welfare. Furthermore, the animals were under full anaesthesia and not
exposed to any additional manipulation due to the inclusion in this study. Therefore,




The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Physiological Sciences, Faculty of Veterinary Medicine,
Warsaw University of Life Sciences, Nowoursynowska 159, 02-776 Warsaw,
Poland. 2Department of Molecular Biology and Genetics, Faculty of Science,
SB Building, Bilkent University, 06800 Ankara, Turkey. 3Institute of Veterinary
Pathology, Freie Universitaet Berlin, Robert-von-Ostertag-Strasse 15, Building
31, 14163 Berlin, Germany. 4Department of Anatomy, Physiology and
Biochemistry, Swedish University of Agricultural Sciences, Box 7011, 75007
Uppsala, Sweden. 5Department of Pathology and Veterinary Diagnostics,
Faculty of Veterinary Medicine, Warsaw University of Life Sciences,
Nowoursynowska 159, 02-776 Warsaw, Poland. 6Veterinary Clinic ‘Elwet’,
Niepodleglosci 24/30, 02-653 Warsaw, Poland. 7Department of Large Animal
Diseases with Clinic, Faculty of Veterinary Medicine, Warsaw University of Life
Sciences, Nowoursynowska 100, 02-797 Warsaw, Poland.
Received: 10 February 2016 Accepted: 1 November 2017
References
1. Egenvall A, Bonnett BN, Ohagen P, Olson P, Hedhammar A, von Euler H.
Incidence of and survival after mammary tumors in a population of over
80,000 insured female dogs in Sweden from 1995 to 2002. Prev Vet Med.
2005;69:109–27.
2. Misdorp W. In: Meuten DJ, editor. Tumors of the mammary gland. 4th ed.
Ames: Iowa State Press; 2002. p. 575–606.
3. Shafiee R, Javanbakht J, Atyabi N, Kheradmand P, Kheradmand D, Bahrami
A, et al. Diagnosis, classification and grading of canine mammary tumours
as a model to study human breast cancer: an Clinico-Cytohistopathological
study with environmental factors influencing public health and medicine.
Cancer Cell Int. 2013;13:79.
4. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF,
et al. Refinement of breast cancer classification by molecular
characterization of histological special types. J Pathol. 2008;216:141–50.
5. Gilbertson SR, Kurzman ID, Zachrau RE, Hurvitz AI, Black MM. Canine
mammary epithelial neoplasms: biologic implications of morphologic
characteristics assessed in 232 dogs. Vet Pathol. 1983;20:127–42.
Bulkowska et al. BMC Cancer  (2017) 17:728 Page 16 of 17
6. Hellmen E, Svensson S. Progression of canine mammary tumours as
reflected by DNA ploidy in primary tumours and their metastases. J Comp
Pathol. 1995;113:327–42.
7. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S, Contag CH. Animal models
of bone metastasis. Cancer. 2003;97(Suppl 3):748–57.
8. Al-Kahiry W, Omer HH, Saeed NM, Hamid GA. Late presentation of breast
cancer in Aden, Yemen. Gulf J Oncolog. 2011;9:7–11.
9. Boggs RM, Wright ZM, Stickney MJ, Porter WW, Murphy KE. MicroRNA
expression in canine mammary cancer. Mamm Genome. 2008;19:561–9.
10. Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, Castle J, et al.
Comparative expression pathway analysis of human and canine mammary
tumors. BMC Genomics. 2009;10:135.
11. Krol M, Motyl T. Exploiting cancer genomics in pet animals to gain advantage
for personalized medicine decisions. J Appl Genet. 2014;55:337–41.
12. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al.
MicroRNA gene expression deregulation in human breast cancer. Cancer
Res. 2005;65:7065–70.
13. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al.
Human microRNA genes are frequently located at fragile sites and genomic
regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999–3004.
14. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH,
et al. Transactivation of miR-34a by p53 broadly influences gene expression
and promotes apoptosis. Mol Cell. 2007;26:745–52.
15. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA
levels by histone deacetylase inhibition. Cancer Res. 2006;66:1277–81.
16. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-
27a targets genes that regulate specificity protein transcription factors and
the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res.
2007;67:11001–11.
17. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis
initiated by microRNA-10b in breast cancer. Nature. 2007;449:682–8.
18. von Deetzen MC, Schmeck BT, Gruber AD, Klopfleisch R. Malignancy associated
microRNA expression changes in canine mammary cancer of different
malignancies. ISRN Vet Sci. 2014; https://doi.org/10.1155/2014/148597.
19. Hellmen E, Bergstrom R, Holmberg L, Spangberg IB, Hansson K, Lindgren A.
Prognostic factors in canine mammary tumors: a multivariate study of 202
consecutive cases. Vet Pathol. 1993;30:20–7.
20. Misdorp W, Else RW, Hellmen E, Lipscomb TP. Histologic classification of
mammary tumor of the dog and the cat in: WHO international histological
classification tumor of domestic animals. Washington, DC. 1999;7:3–29.
21. Elston CW, Ellis IO. Assessment of histological grade. In: Elston CW, Ellis IO,
editors. Systemic pathology: the breast, vol. 13. 3rd ed. Edinburgh: Churchill-
Livingstone; 1998. p. 365–84.
22. Rossum Gv. Python tutorial. Technical Report CS-R9526. Centrum voor
Wiskunde en Informatica (CWI), Amsterdam. 1995.
23. Hunter JD. Matplotlib: a 2D graphics environment. Comput Sci Eng. 2007;9:90–5.
24. Blondal T, Jensby Nielsen S, Baker A, Andreasen D, Mouritzen P, Wrang
Teilum M, et al. Assessing sample and miRNA profile quality in serum and
plasma or other biofluids. Methods. 2013;59:S1–6.
25. Kirschner MB, Edelman JJ, Kao SC, Vallely MP, van Zandwijk N, Reid G. The
impact of Hemolysis on cell-free microRNA biomarkers. Front Genet. 2013;4:94.
26. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative
CT method. Nat Protoc. 2008;3:1101–8.
27. Klopfleisch R, Lenze D, Hummel M, Gruber AD. Metastatic canine mammary
carcinomas can be identified by a gene expression profile that partly
overlaps with human breast cancer profiles. BMC Cancer. 2010;10:618.
28. Fu L, Li Z, Zhu J, Wang P, Fan G, Dai Y, et al. Serum expression levels of
microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients.
Oncol Lett. 2016;12:269–74.
29. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation
and deep-sequencing data. Nucleic Acids Res. 2011;39:D152–7.
30. Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B,
et al. miR-10b*, a master inhibitor of the cell cycle, is down-regulated in
human breast tumours. EMBO Mol Med. 2012;4:1214–29.
31. Luo Q, Li X, Li J, Kong X, Zhang J, Chen L, et al. MiR-15a is underexpressed
and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int J Oncol.
2013;43:1212–8.
32. Yang J, Zhang Z, Chen C, Liu Y, Si Q, Chuang TH, et al. MicroRNA-19a-3p
inhibits breast cancer progression and metastasis by inducing macrophage
polarization through downregulated expression of Fra-1 proto-oncogene.
Oncogene. 2014;33:3014–23.
33. Liu XX, Li XJ, Zhang B, Liang YJ, Zhou CX, Cao DX, et al. MicroRNA-26b is
underexpressed in human breast cancer and induces cell apoptosis by
targeting SLC7A11. FEBS Lett. 2011;585:1363–7.
34. Mathsyaraja H, Thies K, Taffany DA, Deighan C, Liu T, Yu L, et al. CSF1-ETS2-
induced microRNA in myeloid cells promote metastatic tumor growth.
Oncogene. 2015;34:3651–61.
35. Zhang N, Wang X, Huo Q, Sun M, Cai C, Liu Z, et al. MicroRNA-30a
suppresses breast tumor growth and metastasis by targeting metadherin.
Oncogene. 2014;33:3119–28.
36. Tanic M, Yanowsky K, Rodriguez-Antona C, Andres R, Marquez-Rodas I,
Osorio A, et al. Deregulated miRNAs in hereditary breast cancer revealed a
role for miR-30c in regulating KRAS oncogene. PLoS One. 2012;7:e38847.
37. O'Day E, Lal A. MicroRNAs and their target gene networks in breast cancer.
Breast Cancer Res. 2010;12:201.
38. Yu J, Li Q, Xu Q, Liu L, Jiang B. MiR-148a inhibits angiogenesis by targeting
ERBB3. J Biomed Res. 2011;25:170–7.
39. Cimino D, De Pitta C, Orso F, Zampini M, Casara S, Penna E, et al. miR148b
is a major coordinator of breast cancer progression in a relapse-associated
microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1.
FASEB J. 2013;27:1223–35.
40. Bisso A, Faleschini M, Zampa F, Capaci V, De Santa J, Santarpia L, et al.
Oncogenic miR-181a/b affect the DNA damage response in aggressive
breast cancer. Cell Cycle. 2013;12:1679–87.
41. Luo Q, Wei C, Li X, Li J, Chen L, Huang Y, et al. MicroRNA-195-5p is a
potential diagnostic and therapeutic target for breast cancer. Oncol Rep.
2014;31:1096–102.
42. Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, et al.
MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of
annexin A1 downregulation in cancers. Oncogene. 2008;27(52):6667–78.
43. He DX, XT G, Jiang L, Jin J, Ma XA. Methylation-based regulatory network
for microRNA 320a in chemoresistant breast cancer. Mol Pharmacol.
2014;86:536–47.
44. Cai J, Guan H, Fang L, Yang Y, Zhu X, Yuan J, et al. MicroRNA-374a activates
Wnt/beta-catenin signaling to promote breast cancer metastasis. J Clin
Invest. 2013;123:566–79.
45. Liu Y, Lai L, Chen Q, Song Y, Xu S, Ma F, et al. MicroRNA-494 is required for
the accumulation and functions of tumor-expanded myeloid-derived
suppressor cells via targeting of PTEN. J Immunol. 2012;188:5500–10.
46. Polyak K, Kalluri R. The role of the microenvironment in mammary gland
development and cancer. Cold Spring Harb Perspect Biol. 2010;2:a003244.
47. Yoshimura H, Michishita M, Ohkusu-Tsukada K, Takahashi K. Increased
presence of stromal myofibroblasts and tenascin-C with malignant
progression in canine mammary tumors. Vet Pathol. 2011;48:313–21.
48. Lancon A, Michaille JJ, Latruffe N. Effects of dietary phytophenols on the
expression of microRNAs involved in mammalian cell homeostasis. J Sci
Food Agric. 2013;93:3155–64.
49. Dong N, Tang X, Xu B. miRNA-181a inhibits the proliferation, migration, and
epithelial-mesenchymal transition of lens epithelial cells. Invest Ophthalmol
Vis Sci. 2015;56:993–1001.
50. Wang L, Zhou L, Jiang P, Lu L, Chen X, Lan H, et al. Loss of miR-29 in
myoblasts contributes to dystrophic muscle pathogenesis. Mol Ther.
2012;20:1222–33.
51. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-invasive
biomarkers for cancer. Mol Cancer. 2010;9:306.
52. Chen J, Yao D, Li Y, Chen H, He C, Ding N, et al. Serum microRNA
expression levels can predict lymph node metastasis in patients with early-
stage cervical squamous cell carcinoma. Int J Mol Med. 2013;32:557–67.
53. Steudemann C, Bauersachs S, Weber K, Wess G. Detection and comparison
of microRNA expression in the serum of Doberman pinschers with dilated
cardiomyopathy and healthy controls. BMC Vet Res. 2013;9:12.
54. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk
N, et al. Haemolysis during sample preparation alters microRNA content of
plasma. PLoS One. 2011;6:e24145.
55. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ.
Circulating microRNAs as novel minimally invasive biomarkers for breast
cancer. Ann Surg. 2010;251:499–505.
56. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Plasma DX. microRNAs are
promising novel biomarkers for early detection of colorectal cancer. Int J
Cancer. 2010;127:118–26.
Bulkowska et al. BMC Cancer  (2017) 17:728 Page 17 of 17
